Looking at eye nerve layers in NOHL gene carriers
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This study uses a special eye scan (OCT) to look at the layer of nerve fibers in the retina of people who carry (or don't carry) a specific gene change linked to Leber Hereditary Optic Neuropathy (NOHL). The goal is to find early warning signs in the blood that might show who is at risk of losing vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must either have one of the three NOHL gene mutations (11778, 3460, or 14484) — or you must not have any of them. Both groups are welcome.
- You must have normal or near-normal vision and have never had optic neuropathy (nerve damage in the eye).
- You must be willing to have an OCT scan (a quick, painless picture of the back of your eye).
- You must sign a consent form and be between 18 and 60 years old.
- You must have French or European health coverage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new, non-invasive ways to measure how the retina (the light-sensing part of the eye) is structured and how well it works. It may help researchers better understand certain vision disorders and how to track them, without surgery or injections.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This study uses a new type of eye camera to take very detailed pictures of the front of the eye (cornea, lens, and nearby areas). It is for people with certain eye conditions or for healthy volunteers.
This study uses a special laser to take detailed images of the eye. It aims to create a database that could help doctors better understand and diagnose eye conditions like glaucoma, macular degeneration, and retinal diseases.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This study tests whether nicotinamide (vitamin B3) can slow or improve vision loss in people with a specific form of LHON. You may be able to join if your symptoms began recently and you have not taken certain other treatments.
Hear when a new Leber Hereditary Optic Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.